Skip to content
All news
Earnings

Lockheed Martin Posts Record $230B Backlog, Beats Q2 Expectations

Lockheed Martin reported stronger-than-expected Q2 results, ending the quarter with a record backlog of $230 billion, up $64 billion year-over-year, driven by major defense awards including a $35B THAAD contract.

July 24, 2026
2 min read
Source: Benzinga
Share:

Key Numbers

backlog
$230B
backlog increase
$64B
THAAD contract
$35B
GMLRS contract
$3B

Lockheed Martin Corp. (NYSE:LMT) reported stronger-than-expected second-quarter results on Thursday, driven by higher sales and earnings, and ended the quarter with a record backlog of $230 billion. The backlog, the largest in the company’s history, increased by about $64 billion from a year earlier.

Key Financial Highlights

MetricValue
Record Backlog$230 billion
Year-over-Year Increase$64 billion
Major Contracts$35B (THAAD) + $3B (GMLRS)

Key Takeaways from the Report

During the quarter, Lockheed secured several major defense awards, including a $35 billion Terminal High Altitude Area Defense (THAAD) interceptor contract and a $3 billion Guided Multiple Launch Rocket System (GMLRS) contract. These awards significantly boosted the backlog.

Future Guidance

The company stated that the record backlog will fuel sales growth for years to come, without providing specific numerical guidance for the next quarter.

Impact on Stock

The report did not mention an immediate impact on LMT stock, but the strong performance and record backlog reflect customer confidence in the company's products.

What This Means for Investors

The massive backlog provides clear visibility into future revenues, reducing volatility risk. However, investors should monitor contract execution and associated costs.

Frequently Asked Questions

The backlog reached $230 billion, the highest in the company's history.

Found this useful? Share it

Share:
This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.